Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RAD51B del |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| RAD51B del | uterus leiomyosarcoma | predicted - sensitive | Olaparib + Temozolomide | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Temodar (temozolomide) combination treatment resulted in stable disease and progression-free survival lasting 980 days in a patient with advanced uterine leiomyosarcoma harboring a homozygous deletion of RAD51B (PMID: 37467452). | 37467452 | |
| RAD51B del | ovarian cancer | predicted - sensitive | unspecified PARP inhibitor | Case Reports/Case Series | Actionable | In a clinical study, PARP inhibitor monotherapy (niraparib (n=1), olaparib (n=5) or rucaparib), resulted in a median progression-free survival (PFS) of 25.4 mo and an overall survival (OS) of 51.8 mo in ovariant patients with homozygous deletion of homologous recombination repair (HRR) genes (n=8), including RAD51B (n=1), compared to a median PFS of 4.9 mo and OS of 18.5 mo in patients without HRR gene alterations (n=198) (PMID: 42133897). | 42133897 |